切换至 "中华医学电子期刊资源库"

中华肾病研究电子杂志 ›› 2022, Vol. 11 ›› Issue (05) : 281 -284. doi: 10.3877/cma.j.issn.2095-3216.2022.05.007

综述

继发性甲状旁腺功能亢进的治疗研究进展
刘文1, 罗丹1, 代小雨1, 鲜于剑波1, 于颖娟1, 钟春林1, 王东1,()   
  1. 1. 621000 绵阳市中心医院普通外科
  • 收稿日期:2022-02-23 出版日期:2022-10-28
  • 通信作者: 王东

Progress in the research on the treatment of secondary hyperparathyroidism

Wen Liu1, Dan Luo1, Xiaoyu Dai1, Jianbo Xianyu1, Yingjuan Yu1, Chunlin Zhong1, Dong Wang1,()   

  1. 1. Department of General Surgery, Mianyang Central Hospital, Mianyang 621000, Sichuan Province, China
  • Received:2022-02-23 Published:2022-10-28
  • Corresponding author: Dong Wang
引用本文:

刘文, 罗丹, 代小雨, 鲜于剑波, 于颖娟, 钟春林, 王东. 继发性甲状旁腺功能亢进的治疗研究进展[J/OL]. 中华肾病研究电子杂志, 2022, 11(05): 281-284.

Wen Liu, Dan Luo, Xiaoyu Dai, Jianbo Xianyu, Yingjuan Yu, Chunlin Zhong, Dong Wang. Progress in the research on the treatment of secondary hyperparathyroidism[J/OL]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2022, 11(05): 281-284.

继发性甲状旁腺功能亢进(SHPT)是晚期慢性肾病患者中最常见的并发症之一,患者体内的高水平甲状旁腺激素会引起骨骼异常和血管钙化、增加心血管事件的发生率。目前SHPT的治疗方法有药物治疗、介入治疗、传统手术治疗等。本文对SHPT治疗的研究进展作一综述,旨在为临床选择SHPT治疗方式提供参考。

Secondary hyperparathyroidism (SHPT) is one of the most common complications in patients with advanced chronic kidney disease. High levels of parathyroid hormone in the patients can cause bone abnormalities and vascular calcification, and increase the incidence of cardiovascular events. At present, SHPT can be treated by drug therapy, interventional therapy, and traditional surgery, etc. This article reviewed the progress of research on treatment of SHPT so as to provide reference for clinical selection of therapies for SHPT.

图2 继发性甲状旁腺功能亢进的治疗方式注:SHPT:继发性甲状旁腺功能亢进;PEIT:percutaneous ethanol injection therapy,经皮乙醇注射疗法;RFA:radio-frequency ablation,射频消融;LA:laser ablation,激光消融;sPTX:subtotal parathyroidectomy,甲状旁腺次全切除术;tPTX:total parathyroidectomy,全甲状旁腺切除术;tPTX+AT:tPTX plus autotransplantation,全甲状旁腺切除术加自体移植术
[32]
杨晓琦,陈安举,王田田,等. 继发性甲状旁腺功能亢进甲状旁腺全切除术的探讨[J]. 中华耳鼻咽喉头颈外科杂志2020, 55(2): 98-103.
[33]
韩伟,吴云,张野. 右美托咪定对肾源性继发性甲状旁腺功能亢进症患者术后复发的影响[J]. 国际麻醉学与复苏杂志2020, 41(12): 1146-1150.
[1]
Sun X, Zhang X, Zhang L, et al. Relationship between intraoperative measured parameters of parathyroid gland and pathological patterns in patients with secondary hyperparathyroidism [J]. Ann Transl Med, 2021, 9(2): 99.
[2]
Wen P, Xu L, Zhao S, et al. Risk factors for severe hypocalcemia in patients with secondary hyperparathyroidism after total parathyroidectomy [J]. Int J Endocrinol, 2021, 2021: 6613659.
[3]
Habas E Sr, Eledrisi M, Khan F, et al. Secondary hyperparathyroidism in chronic kidney disease: pathophysiology and management [J]. Cureus, 2021, 13(7): e16388.
[4]
陈聪,陈祖辉,尹良红,等. 我国独立血液透析中心投资发展策略分析[J]. 临床医学工程2021, 28(S1): 1-4.
[5]
Galassi A, Ciceri P, Fasulo E, et al. Management of secondary hyperparathyroidism in chronic kidney disease: a focus on the elderly [J]. Drugs Aging, 2019, 36(10): 885-895.
[6]
Wu Y, Liu Y, Huang T, et al. Application of nanocarbon negative imaging technology in surgery for secondary hyperparathyroidism [J]. Gland Surg, 2021, 10(8): 2455-2461.
[7]
Nakamura M, Tanaka K, Fujii T. Hyperparathyroidism caused by distant pulmonary lesions and parathyromatosis after ethanol injection/parathyroidectomy for secondary hyperparathyroidism [J]. Hemodial Int, 2017, 21(3): E45-E49.
[8]
梁辉,王文兵. 碳酸镧联合骨化三醇治疗维持性血液透析继发甲状旁腺功能亢进症的临床观察[J]. 检验医学与临床2021, 18(10): 1485-1488.
[9]
陈孜瑾,陈晓农. 新型非含钙磷结合剂在慢性肾脏病-矿物质和骨异常患者中的临床应用[J]. 临床肾脏病杂志2018, 18(9): 582-585.
[10]
代红梅,龚孝春,王瑞宁. 烟酰胺联合司维拉姆治疗血液透析高磷血症的临床研究[J]. 现代药物与临床2018, 33(12): 3349-3353.
[11]
周加军,张凌. 活性维生素D及其类似物在CKD-MBD中的应用[J].中国血液净化2018, 17(6): 370-373.
[12]
李勇飞,杜庆生,李小妹. 大剂量骨化三醇冲击治疗终末期肾病并发继发性甲状旁腺功能亢进的临床效果观察[J].吉林医学2020, 41(5): 1141-1143.
[13]
刘威,刘昊虹,周兵,等. 骨化三醇和阿法骨化醇治疗血液透析患者继发性甲状旁腺功能亢进的疗效分析[J]. 吉林医学2017, 38(5): 872-873.
[14]
Pun PH, Abdalla S, Block GA, et al. Cinacalcet, dialysate calcium concentration, and cardiovascular events in the EVOLVE trial [J]. Hemodial Int, 2016, 20(3): 421-431.
[15]
Subramanian R, Zhu X, Kerr SJ, et al. Nonclinical pharmacokinetics, disposition, and drug-drug interaction potential of a novel d-amino acid peptide agonist of the calcium-sensing receptor AMG 416 (etelcalcetide) [J]. Drug Metab Dispos, 2016, 44(8): 1319-1331.
[16]
Harada K, Fujioka A, Konno M, et al. Pharmacology of Parsabiv® (etelcalcetide, ONO-5163/AMG 416), a novel allosteric modulator of the calcium-sensing receptor, for secondary hyperparathyroidism in hemodialysis patients [J]. Eur J Pharmacol, 2019, 842: 139-145.
[17]
Block GA, Bushinsky DA, Cheng S, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial [J]. JAMA, 2017, 317(2): 156-164.
[18]
徐骏,王笑薇,刘旻,等. 碳酸镧联合西那卡塞、骨化三醇对血液透析伴继发性甲状旁腺功能亢进症的疗效[J]. 实用医学杂志2021, 37(1): 82-86.
[19]
Chávez KV, Márquez-González H, Chavez-Tostado M. The usefulness of intraoperative PTH as a predictor for successful parathyroidectomy in secondary hyperparathyroidism [J]. Front Surg, 2021, 8: 696469.
[20]
Sharma J, Halkar R, Weber CJ. Imaging of parathyroid glands in end stage renal disease [J]. Semin Dial, 2017, 30(4): 369-372.
[21]
Qin X, Wang B, Li B, et al. Value of contrast-enhanced ultrasonography in radiofrequency ablation of secondary hyperparathyroidism [J]. Ren Fail, 2021, 43(1): 445-451.
[22]
吴静静,陆志强,刘凌晓. 射频消融术(RFA)治疗继发性甲状旁腺功能亢进(SHPT)的安全性及有效性分析[J]. 复旦学报(医学版), 2020, 47(2): 187-191.
[23]
吕珂,李建初,姜玉新. 超声造影临床应用进展[J]. 中国医学影像技术2021, 37(12): 1761-1764.
[24]
方建强,赵维安,李庆,等. 超声引导下微波消融治疗继发性甲状旁腺功能亢进的短期疗效分析[J]. 中国超声医学杂志2020, 36(5): 476-479.
[25]
于明安,姚力,彭丽丽,等. 超声引导下微波消融持续或复发性继发甲旁亢的临床研究[J]. 中国超声医学杂志2017, 33(3) : 202 -205.
[26]
Zhuo L, Peng LL, Zhang YM, et al. US-guided microwave ablation of hyperplastic parathyroid glands: safety and efficacy in patients with end-stage renal disease-a pilot study [J].Radiology, 2017, 282(2): 576-584.
[27]
Andrioli M, Riganti F, Pacella CM, et al. Long-term effectiveness of ultrasound-guided laser ablation of hyperfunctioning parathyroid adenomas: present and future perspectives [J]. AJR Am J Roentgenol, 2012, 199(5): 1164-1168.
[28]
Fei M, Xu D, Lai Y, et al. Comparison of different parathyroid autograft project after total parathyroidectomy in patients with secondary hyperparathyroidism [J]. Am J Otolaryngol, 2021, 42(6): 103085.
[29]
高恒元,许楠,罗勋鹏,等. 72例继发性甲状旁腺功能亢进行甲状旁腺次全切除术的治疗分析[J]. 中国现代普通外科进展2017, 20(9): 684-686, 691.
[30]
Wang M, Chen B, Zou X, et al. A nomogram to predict hungry bone syndrome after parathyroidectomy in patients with secondary hyperparathyroidism [J]. J Surg Res, 2020, 255: 33-41.
[31]
Ge Y, Yang G, Wang N, et al. Bone metabolism markers and hungry bone syndrome after parathyroidectomy in dialysis patients with secondary hyperparathyroidism [J]. Int Urol Nephrol, 2019, 51(8): 1443-1449.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志(电子版), 2024, 21(11): 1089-1091.
[2] 李晓妮, 卫青, 孟庆龙, 牛丽莉, 田月, 吴伟春, 朱振辉, 王浩. 超声心动图在孤立性左心室心尖发育不良疾病中的应用价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 937-942.
[3] 陈慧, 姚静, 张宁, 刘磊, 马秀玲, 王小贤, 方爱娟, 管静静. 超声心动图在多发性骨髓瘤心脏淀粉样变中的诊断价值[J/OL]. 中华医学超声杂志(电子版), 2024, 21(10): 943-949.
[4] 李刘庆, 陈小翔, 吕成余. 全腹腔镜与腹腔镜辅助远端胃癌根治术治疗进展期胃癌的近中期随访比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 23-26.
[5] 刘世君, 马杰, 师鲁静. 胃癌完整系膜切除术+标准D2根治术治疗进展期胃癌的近中期随访研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 27-30.
[6] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[7] 常小伟, 蔡瑜, 赵志勇, 张伟. 高强度聚焦超声消融术联合肝动脉化疗栓塞术治疗原发性肝细胞癌的效果及安全性分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 56-59.
[8] 韩戟, 杨力, 陈玉. 腹部形态CT参数与完全腹腔镜全胃切除术术中失血量的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 88-91.
[9] 王露, 周丽君. 全腹腔镜下远端胃大部切除不同吻合方式对胃癌患者胃功能恢复、并发症发生率的影响[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 92-95.
[10] 孙一娇, 包润发, 董平, 束翌俊. PBL结合手术视频剪辑教学在普通外科专科医师规范化培训中的应用与思考[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 96-99.
[11] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[12] 孙莲, 马红萍, 吴文英. 局部进展期甲状腺癌患者外科处理[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 112-114.
[13] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[14] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[15] 刘柏隆, 周祥福. 女性尿失禁吊带手术并发症处理的经验分享[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 127-127.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?